Nasdaq · CIK 0001994702
KYTX Kyverna Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing May 29, 2026. Close $6.39 on Oct 9, 2026, +4% from the 52-week low and -43% from the high.
Kyverna Therapeutics, Inc. (KYTX) has 30 SEC Form 4 filings on file from 17 insiders, the latest filed on May 29, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
3 open-market trades have been scored at KYTX. The newest: Westlake BioPartners Opportunity Fund I, L.P. (10% owner) bought $1000k of stock on Dec 18, 2025, filed Dec 22, 2025, scored 43 (moderate). 2 insiders bought within 14 days of each other around Dec 18, 2025.
KYTX closed at $6.39 on Oct 9, 2026, 4% above its 52-week low and 43% below its 52-week high.
5 Form 144 notices of planned sales are on file, the latest filed Apr 17, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Kyverna Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Westlake BioPartners Opportunity Fund I, L.P. owner buy | $1000k 133,333 shares | +18% | - | |
| 51Moderate | Beth C Seidenberg director buy | $1000k 133,333 shares | +18% | - | |
| 14Weak | Karen Marie Walker Chief Technology Officer sell | $293k 23,998 shares | -51% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 17, 2026 | KAREN WALKER Officer | 10,000 0.02% of outstanding | $95k | Apr 17, 2026 | $23k |
| Apr 14, 2026 | KAREN WALKER Officer | 2,459 0.00% of outstanding | $23k | Apr 14, 2026 | none |
| Apr 7, 2026 | DANIEL SPIEGELMAN Director | 17,578 0.03% of outstanding | $163k | Apr 7, 2026 | $140k |
| Mar 31, 2026 | DANIEL SPIEGELMAN Director | 16,634 0.03% of outstanding | $140k | Mar 31, 2026 | none |
| Dec 15, 2025 | KAREN WALKER Officer | 23,998 0.05% of outstanding | $211k | Dec 15, 2025 | none |
Transactions
The newest 50 of 51 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | Mert Aktar director | AGrant or award Common Stock | +5,093 | $0.00 | $0 | 21,727 | May 29, 2026 |
| May 27, 2026 | Beth C Seidenberg director | AGrant or award Common Stock | +5,093 | $0.00 | $0 | 21,727 | May 29, 2026 |
| May 27, 2026 | Fred E Cohen director | AGrant or award Common Stock | +5,093 | $0.00 | $0 | 21,727 | May 29, 2026 |
| May 27, 2026 | Ian T Clark director | AGrant or award Common Stock | +5,093 | $0.00 | $0 | 21,727 | May 29, 2026 |
| May 27, 2026 | Christi Shaw Executive Chairperson | FTax withholding Common Stock | -4,194 | $8.59 | $36k | 66,741 | May 29, 2026 |
| May 27, 2026 | Mert Aktar director | AGrant or award Stock Option (right to buy)derivative | +20,582 | $0.00 | $0 | 20,582 | May 29, 2026 |
| May 27, 2026 | Ian T Clark director | AGrant or award Stock Option (right to buy)derivative | +20,582 | $0.00 | $0 | 20,582 | May 29, 2026 |
| May 27, 2026 | Fred E Cohen director | AGrant or award Stock Option (right to buy)derivative | +20,582 | $0.00 | $0 | 20,582 | May 29, 2026 |
| May 27, 2026 | Beth C Seidenberg director | AGrant or award Stock Option (right to buy)derivative | +20,582 | $0.00 | $0 | 20,582 | May 29, 2026 |
| May 18, 2026 | Gregory S. Martini Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +325,000 | $0.00 | $0 | 325,000 | May 20, 2026 |
| May 4, 2026 | Nadia Dac Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | May 6, 2026 |
| Mar 13, 2026 | Marc Grasso Chief Financial Officer | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | Mar 17, 2026 |
| Mar 13, 2026 | Warner Weston Biddle Chief Executive Officer | AGrant or award Common Stock | +58,000 | $0.00 | $0 | 58,000 | Mar 17, 2026 |
| Mar 13, 2026 | Naji Gehchan See Remarks | AGrant or award Common Stock | +18,000 | $0.00 | $0 | 18,000 | Mar 17, 2026 |
| Mar 13, 2026 | Marc Grasso Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Mar 17, 2026 |
| Mar 13, 2026 | Warner Weston Biddle Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +350,000 | $0.00 | $0 | 350,000 | Mar 17, 2026 |
| Mar 13, 2026 | Naji Gehchan See Remarks | AGrant or award Stock Option (right to buy)derivative | +105,000 | $0.00 | $0 | 105,000 | Mar 17, 2026 |
| Feb 24, 2026 | Andrew Craig Miller director | AGrant or award Common Stock | +11,006 | $0.00 | $0 | 11,006 | Mar 4, 2026 |
| Feb 24, 2026 | Andrew Craig Miller director | AGrant or award Stock Option (right to buy)derivative | +42,945 | $0.00 | $0 | 42,945 | Mar 4, 2026 |
| Feb 24, 2026 | Sravan Kumar Emany director | AGrant or award Common Stock | +11,006 | $0.00 | $0 | 11,006 | Feb 26, 2026 |
| Feb 24, 2026 | Sravan Kumar Emany director | AGrant or award Stock Option (right to buy)derivative | +42,945 | $0.00 | $0 | 42,945 | Feb 26, 2026 |
| Feb 9, 2026 | Mayobanex Pujols Chief Technology Officer | AGrant or award Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Feb 11, 2026 |
| Jan 12, 2026 | Christi Shaw Executive Chairperson | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 46,634 | Jan 14, 2026 |
| Jan 12, 2026 | Christi Shaw Executive Chairperson | AGrant or award Common Stock | +24,301 | $0.00 | $0 | 70,935 | Jan 14, 2026 |
| Jan 12, 2026 | Christi Shaw Executive Chairperson | AGrant or award Stock Option (right to buy)derivative | +185,000 | $0.00 | $0 | 185,000 | Jan 14, 2026 |
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. owner | POpen-market purchase Common Stockindirect: See Footnote | +133,333 | $7.50 | $1000k | 869,317 | Dec 22, 2025 |
| Dec 18, 2025 | Beth C Seidenberg director | POpen-market purchase Common Stockindirect: See Footnote | +133,333 | $7.50 | $1000k | 869,317 | Dec 22, 2025 |
| Dec 15, 2025 | Karen Marie Walker Chief Technology Officer | MOption exercise Common Stock10b5-1 | +23,998 | $4.83 | $116k | 46,634 | Dec 17, 2025 |
| Dec 15, 2025 | Karen Marie Walker Chief Technology Officer | SOpen-market sale Common Stock10b5-1 | -23,998 | $12.20 | $293k | 22,636 | Dec 17, 2025 |
| Dec 15, 2025 | Karen Marie Walker Chief Technology Officer | MOption exercise Stock option (right to buy)derivative10b5-1 | -23,998 | $0.00 | $0 | 85,865 | Dec 17, 2025 |
| Jun 30, 2025 | Marc Grasso Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | -450,000 | $0.00 | $0 | 450,000 | Jul 1, 2025 |
| May 29, 2025 | Mert Aktar director | AGrant or award Common Stock | +16,634 | $0.00 | $0 | 16,634 | Jun 2, 2025 |
| May 29, 2025 | Ian T Clark director | AGrant or award Common Stock | +16,634 | $0.00 | $0 | 16,634 | Jun 2, 2025 |
| May 29, 2025 | Fred E Cohen director, owner | AGrant or award Common Stock | +16,634 | $0.00 | $0 | 16,634 | Jun 2, 2025 |
| May 29, 2025 | Daniel K Spiegelman director | AGrant or award Common Stock | +16,634 | $0.00 | $0 | 16,634 | Jun 2, 2025 |
| May 29, 2025 | Beth C Seidenberg director, owner | AGrant or award Common Stock | +16,634 | $0.00 | $0 | 16,634 | Jun 2, 2025 |
| May 29, 2025 | Christi Shaw Executive Chairperson | AGrant or award Common Stock | +16,634 | $0.00 | $0 | 16,634 | Jun 2, 2025 |
| May 29, 2025 | Mert Aktar director | AGrant or award Stock Option (right to buy)derivative | +65,351 | $0.00 | $0 | 65,351 | Jun 2, 2025 |
| May 29, 2025 | Ian T Clark director | AGrant or award Stock Option (right to buy)derivative | +65,351 | $0.00 | $0 | 65,351 | Jun 2, 2025 |
| May 29, 2025 | Daniel K Spiegelman director | AGrant or award Stock Option (right to buy)derivative | +65,351 | $0.00 | $0 | 65,351 | Jun 2, 2025 |
| May 29, 2025 | Christi Shaw Executive Chairperson | AGrant or award Stock Option (right to buy)derivative | +65,351 | $0.00 | $0 | 65,351 | Jun 2, 2025 |
| May 29, 2025 | Fred E Cohen director, owner | AGrant or award Stock Option (right to buy)derivative | +65,351 | $0.00 | $0 | 65,351 | Jun 2, 2025 |
| May 29, 2025 | Beth C Seidenberg director, owner | AGrant or award Stock Option (right to buy)derivative | +65,351 | $0.00 | $0 | 65,351 | Jun 2, 2025 |
| Apr 11, 2025 | Ryan Alexander Jones Chief Financial Officer | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 55,950 | Apr 15, 2025 |
| Apr 11, 2025 | Karen Marie Walker Chief Technology Officer | AGrant or award Common Stock | +13,000 | $0.00 | $0 | 22,636 | Apr 15, 2025 |
| Apr 11, 2024 | Warner Weston Biddle Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +332,500 | $0.00 | $0 | 332,500 | Apr 15, 2025 |
| Apr 11, 2024 | Karen Marie Walker Chief Technology Officer | AGrant or award Stock Option (right to buy)derivative | +80,000 | $0.00 | $0 | 80,000 | Apr 15, 2025 |
| Apr 11, 2024 | Ryan Alexander Jones Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +74,000 | $0.00 | $0 | 74,000 | Apr 15, 2025 |
| Feb 14, 2025 | Christi Shaw Executive Chairperson | AGrant or award Stock Option (right to buy)derivative | +38,679 | $0.00 | $0 | 38,679 | Feb 19, 2025 |
| Jan 22, 2025 | Naji Gehchan See Remarks | AGrant or award Stock Option (right to buy)derivative | +425,000 | $0.00 | $0 | 425,000 | Jan 24, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Mert Aktardirector
- Warner Weston BiddleChief Executive Officer
- Ian T Clarkdirector
- Fred E Cohendirector, owner
- Nadia DacChief Commercial Officer
- Sravan Kumar Emanycfo, coo, officer, director
- Naji GehchanSee Remarks
- Marc GrassoChief Financial Officer
- Ryan Alexander JonesChief Financial Officer
- Gregory S. MartiniChief Financial Officer
- Andrew Craig Millerdirector
- Mayobanex PujolsChief Technology Officer
- Beth C Seidenbergdirector, owner
- Daniel K Spiegelmandirector
- Christi ShawExecutive Chairperson
- Karen Marie WalkerChief Technology Officer
- Westlake BioPartners Opportunity Fund I, L.P.owner
Questions about KYTX
Answered from the filings on this page, as of the latest one.
Are insiders buying KYTX?
No. In the last 90 days no insider at Kyverna Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KYTX on the open market?
Westlake BioPartners Opportunity Fund I, L.P. (10% owner) bought $1000k of KYTX on Dec 18, 2025 and filed the Form 4 on Dec 22, 2025. InsiderTell scored 43 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Kyverna Therapeutics, Inc.?
17 people have filed a Form 4 at Kyverna Therapeutics, Inc., among them Mert Aktar (director), Warner Weston Biddle (Chief Executive Officer), Ian T Clark (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.